Concurrent treatment of chronic psoriasis and asthma with ustekinumab.

Concurrent treatment of chronic psoriasis and asthma with ustekinumab.

Amarnani Ajay; Rosenthal Ken S; Mercado Jorge M; Brodell Robert T

The Journal of dermatological treatment

2014

2014-02

A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.

Female; Humans; Middle Aged; Chronic Disease; Asthma/*drug therapy; Immunosuppressive Agents/metabolism/*therapeutic use; Inflammation/drug therapy; Interleukin-12/metabolism; Interleukin-23/metabolism; Psoriasis/*drug therapy; Ustekinumab; Antibodies; Injections; Subcutaneous; Monoclonal; Humanized/metabolism/*therapeutic use; Monoclonal/administration & dosage/immunology/therapeutic use

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

63–66

1

25